Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1991-02-08
1992-05-05
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514177, A61K 3156
Patent
active
051108100
ABSTRACT:
Treating human beings with pharmacological quantities of DHEA results in their blood having increased serum DHEA and DHEA-S and lower rates of platelet aggregation. Reducing the rate of platelet aggregation can significantly reduce the incidence or morbidity and mortality from vascular events such as myocardial infarction and stroke, as well as reduce the occurrence of restenosis following vascular interventions. The concentration of DHEA and DHEA-S in the blood and the pre-incubation time of DHEA and DHEA-S with the blood will affect its impact on platelet aggregation. Hence, prior treatment of patients who are at risk with DHEA may produce the most beneficial affects. In addition, treatment of blood with DHEA-S reduces thromboxane production. Thromboxane is produced after platelets are subjected to many different types of agonists and is responsible for recruiting other platelets to aggregate and form a thrombus; therefore, blocking the production of thromboxane will reduce or prevent platelet aggregation.
REFERENCES:
patent: 4898694 (1990-02-01), Schwartz et al.
patent: 4920115 (1990-04-01), Nestler et al.
"Age Changes and Sex Differences in Serum Dehydroepiandrosterone Sulfate Concentrations throughout Adulthood"; Norman Orentreich, Joel L. Brind, Ronald L. Rizer, and Joseph H. Vogelman; Journal of Clinical Endocrinology and Metabolism; vol. 59, No. 3, pp. 551-555; (1984).
"A Prospective Study of Dehydroepiandrosterone Sulfate, Mortality, and Cardiovascular Disease"; Elizabeth Barrett-Connor, M.D., Kay-Tee Khaw, and Samuel S. C. Yen; New Engl. J. Med.; 315:1519-1524 (1986).
"Dehydroepiandrosterone Feeding Prevents Aortic Fatty Streak Formation and Cholesterol Accumulation in Cholesterol-fed Rabbit"; Yadon Arad, Juan J. Badimon, Lina Badimon, Wylie C. Hembree and Henry N. Ginsberg; Arteriosclerosis, 9:159-166 (1989).
"Reduction of Atherosclerosis by Administration of Dehydroepiandrosterone"; Gary B. Gordon, David E. Bush, and Harlan F. Weisman; J. Clin. Invest., 82:712-719 (1988).
"Inhibition of Mammalian Glucose-6-Phosphate Dehydrogenase by Steroids"; Paul A. Marks and Julia Banks; Proc. Natl. Acad. Sci., 46:447-452 (1960).
"Effect of GSH Depletion by 1-Chloro-2, 4-Dinitrobenzine on Human Platelet Aggregation, Arachidonic Acid Oxidative Metabolism and Cytoskeletal Proteins"; A. Bosia, P. Spangenberg, D. Ghigo, R. Heller, W. Losche, G. P. Pescarmona and U. Till; Thrombosis Research 37; 423-434 (1985).
"Human Platelets Modulate Edema Formation in Isolated Rabbit Lungs"; John E Heffner, James A. Cook and Perry V. Halushka; J. Clin. Invest., 84:757-764 (1989).
"DHEA: Miracle Drug?"; Saul Kent; Geriatrics; 37:157-159 (1982).
"Plasma Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate in Patients Undergoing Diagnostic Coronary Angiography"; D. M. Herrington, G. B. Gordon, S. C. Achuff, J. F. Trejo, H. F. Weisman, P. O. Kwiterovich and T. A. Pearson; J. Amer. Coll. Card., 16:862-870 (1990).
Eich David M.
Jesse Robert
Nestler John
Hook Gregory
Virginia Commonwealth University
Waddell Frederick E.
LandOfFree
Method of using dehydroepiandrosterone and dehydroepiandrosteron does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of using dehydroepiandrosterone and dehydroepiandrosteron, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of using dehydroepiandrosterone and dehydroepiandrosteron will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1412555